Main Article Content



Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications to reduce inflammation and pain in clinical practice. The main concern with their use is gastrointestinal and cardiovascular side effects due to inhibition of gastroprotective prostaglandins and imbalance of prostacyclin and thromboxane respectively. NSAIDs function by inhibiting the cyclooxygenase (COX) enzymes. Evidence shows the occurrence of these side effects even with their short term use. Development of NSAID with a goal of superior or similar efficacy but with lower incidences of side effects resulted in the introduction of aceclofenac. Classified as a preferential COX-2 inhibitor, aceclofenac inhibits the COX-2 enzyme preferentially (97 %) as compared to COX-1 (46 %). Lesser inhibition of the COX-1 enzyme results in lower incidences of GI side effects. Also, due to preferential COX-2 selectivity, aceclofenac balances vascular homeostasis and thus has minimal CV risk. The diversity of COX-1 and COX-2 selectivity in NSAIDs has proven clinically important. Encouraging clinical evidence shows that aceclofenac has a favourable safety profile amongst NSAIDs. Our goal in this manuscript is to give a narrative review of clinical evidence of aceclofenac’s safety and tolerability. Based on the data, we can conclude that aceclofenac is an effective analgesic in both acute and chronic inflammatory conditions, with a comparatively low risk of gastrointestinal and cardiovascular adverse effects. This favourable tolerability profile of the drug reflects a reduction in cost associated with adverse events management, from both patient’s and healthcare provider’s perspectives.


Non-Steroidal Anti-Inflammatory Drugs, Pain, Inflammation, NSAID, COX Enzyme, Preferential COX-2 Inhibitor, Aceclofenac, Gastrointestinal Safety, Cardiac Safety.

Article Details

How to Cite
Anu Grover, Eknath Pawar, G. K. Singh, Ashok Gupta, Anil Pareek, Rujul Desai, & Indranil Purkait. (2022). Aceclofenac, a Preferential COX-2 Inhibitor - Appraisal of Safety and Tolerability. Journal of Evolution of Medical and Dental Sciences, 11(7), 690–698.


  1. Rao PNP, Knaus EE. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): cyclooxygenase (COX) Inhibition and Beyond. J Pharm Pharm Sci 1997;11(2):81-110s.
  2. Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum 2004;50(8):2391-9.
  3. Atkinson TJ, Fudin J. Nonsteroidal Antiinflammatory Drugs for Acute and Chronic Pain. Vol. 31, Physical Medicine and Rehabilitation Clinics of North America. Phys Med Rehabil Clin N Am 2020;31(2)219-31.
  4. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003;25(2 Suppl):S32-40.
  5. Hatt KM, Vijapura A, Maitin IB, et al. Safety considerations in prescription of nsaids for musculoskeletal pain: a narrative review. PM and R 2018;10(12):1404-11.
  6. Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011;10(4):655-83.
  7. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med 2004;351(17):1707-9.
  8. Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Agency fo Healthc Res Qual 2011;(38).
  9. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001;61(9):1351-78.
  10. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004;5(6):1347-57.
  11. Yang JH, Suk KS, Lee BH, et al. Efficacy and safety of different aceclofenac treatments for chronic lower back pain: Prospective, randomized, single center, open-label clinical trials. Yonsei Med J 2017;58(3):637-43.
  12. Ward DE, Veys EM, Bowdler JM, et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14(6):656-62.
  13. Chalini S, Raman U. Comparative efficacy of aceclofenac and etoricoxib in post-extraction pain control: randomized control trial. Indian J Dent Res 2005;16(2):47-50.
  14. Seymour RA, Frame J, Negus TW, et al. The comparative efficacy of aceclofenac and ibuprofen in postoperative pain after third molar surgery. Br J Oral Maxillofac Surg 1998;36(5):375-9.
  15. Kornasoff D, Frerick H, Bowdler J, et al. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 1997;16(1):32-8.
  16. Pareek A, Chandurkar N, Gupta A, et al. Efficacy and safety of aceclofenac-CR and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain 2011;12(5):546-53.
  17. Pareek A, Chandurkar N, Chandanwale AS, et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009;18(12):1836-42.
  18. Martín-Mola E, Gijón-Baños J, Ansoleaga JJ. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheumatol Int 1995;15(3):111-6.
  19. Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol 2003;22(2):127-35.
  20. Letzel H, Mégard Y, Lamarca R, et al. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol 2006;129(2):162-8.
  21. Pareek A, Chandurkar NB, Patil RT, et al. Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized comparative study with aceclofenac. Eur J Obstet Gynecol Reprod Biol 2010;152(1):86-90.
  22. Lima PVP, Fontanella V. Analgesic efficacy of aceclofenac after surgical extraction of impacted lower third molars. Int J Oral Maxillofac Surg 2006;35(6):518-21.
  23. Hinz B, Rau T, Auge D, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003;74(3):222-35.
  24. Schmidt M, Lamberts M, Olsen AMS, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016;37(13):1015-23.
  25. Pelletier JP, Martel-Pelletier J, Rannou F, et al. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016;45(4):S22-7.
  26. Ribeiro AQ, Sevalho G, César CC. The use of nonsteroidal anti-inflammatory drugs and the occurrence of gastric lesions among patients undergoing upper endoscopy in a university hospital in Brazil. Clinics 2006;61(5):409-16.
  27. Yanagawa A, Endo T, Kusakari K, Kudo T, Shimada J, Mizushima Y. Endoscopic evaluation of aceclofenac-induced gastroduodenal mucosal damage: a double-blind comparison with sodium diclofenac and placebo. Japanese J Rheumatol 1998;8(3):249-59.
  28. Huskisson EC, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm 2000;17(1):1-7.
  29. Ward DE, Veys EM, Bowdler JM, et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14(6):656-62.
  30. Pasero G, Marcolongo R, Semi U, et al. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenar in the treatment of rheumatoid arthritis. Curr Med Res Opin 1995;13(6):305-15.
  31. Kornasoff D, Maisenbacher J, Bowdler J, et al. The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol Int 1996;15(6):225-30.
  32. Torri G, Vignati C, Agrifoglio E, et al. Aceclofenac versus piroxicam in the management of osteoarthritis of the knee: a double-blind controlled study. Curr Ther Res 1994;55(5):576-83.
  33. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Use. A report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol 2008;52(18):1502-17.
  34. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152(2):101-13.
  35. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5(9):1040-5.
  36. Pareek A, Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin 2013;29(7):849-59.
  37. Grau M, Guasch J, Montero JL, et al. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneimittelforschung 1991;41(12):1265-76.
  38. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156(14):1530-6.
  39. Laporte JR, Ibáñez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27(6):411-20.
  40. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS Project). Drug Saf 2012;35(12):1127-46.
  41. Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience. Curr Med Res Opin 2006;22(5):977-88.
  42. Patil PR, Jaida J, Palani A, et al. A comparative study of efficacy and safety of diclofenac and aceclofenac in the treatment of osteoarthritis patients. J Drug Deliv Ther 2012;2(4):139-43.
  43. Chunduri NS, Kollu T, Goteki VR, et al. Efficacy of aceclofenac and diclofenac sodium for relief of postoperative pain after third molar surgery: a randomised open label comparative study. J Pharmacol Pharmacother 2013;4(2):144-5.
  44. Pasero G, Ruju G, Marcolongo R, et al. Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: a double-blind, controlled study. Curr Ther Res 1994;55(7):833-42.
  45. Kornasoff D, Frerick H, Bowdler J, et al. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 1997;16(1):32-8.
  46. Busquier MP, Calero E, Rodriguez M, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 1997;16(2):154-9.
  47. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2006;5(1):83-94.
  48. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.
  49. Arfè A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.
  50. Masclee GMC, Straatman H, Arfè A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS One 2018;13(11):e0204746.
  51. Fallach N, Chodick G, Tirosh M, et al. Pain pharmacotherapy in a large cohort of patients with osteoarthritis: a real-world data analysis. Rheumatol Ther 2021;8(3):1129-41.
  52. Muppur A, Nandagopal A. Comparative study of Aceclofenac with Etoricoxib on degree of analgesia and assessment of incidence of hypertension and peptic ulcer in rheumatoid arthritis patients. IOSR J Dent Med Sci 2014;13(11):34-40.
  53. Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 2013;27(2):223-30.
  54. Aceclofenac 100 mg film-coated Tablets - Summary of Product Characteristics (SPC) - (eMC).
  55. Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol 2018;2018:5253623.
  56. Bolten WW. NSAIDs. In: Local treatment of inflammatory joint diseases: benefits and risks. National Institute of Diabetes and Digestive and Kidney Diseases 2015:63-70.
  57. Agúndez JAG, Lucena MI, Martínez C, et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011;7(7):817-28.
  58. Raber A, Heras J, Costa J, et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag 2007;3(2):225-30.